The treatment landscape for metastatic hormone-sensitive prostate cancer (HSPC) is undergoing a critical reassessment, moving beyond simply adding more intensive therapies to a focus on precision and identifying which patients will truly benefit. Presented at the 2026 ASCO Genitourinary Cancers Symposium, Dr. Christopher Sweeney’s analysis underscores a growing recognition that “more” isn’t always better, and that a more nuanced approach – leveraging investigator-led trials, companion diagnostics, and biomarker-driven strategies – is essential to improving outcomes and minimizing unnecessary toxicity. This shift reflects a broader trend in oncology towards personalized medicine, but is particularly acute in HSPC given the increasing number of available treatment options and the complexity of predicting response.
Key Takeaways
- Investigator-Initiated Trials are Crucial: Data from these trials, often closer to real-world scenarios, are vital for understanding treatment efficacy and identifying biomarkers.
- PSA Nadir Remains a Key Indicator: Achieving a PSA level below 0.2 within 6-7 months of treatment continues to correlate with a 50% 8-year overall survival rate, highlighting the importance of maximizing treatment intensification to reach this benchmark.
- Biomarker-Driven Approaches are the Future: While current options like PARP inhibitors and LuPSMA show promise, optimized dosing and robust biomarker selection are needed to define which patients will benefit most.
The Evolving Standard of Care
For decades, the treatment of metastatic HSPC has steadily evolved. From initial reliance on androgen deprivation therapy (ADT) alone, the addition of docetaxel chemotherapy, followed by newer androgen-signaling inhibitors like enzalutamide, has demonstrably improved survival – doubling 8-year overall survival rates from approximately 25% to 50%. The ENZAMET study, with its long-term follow-up data presented at ASCO GU 2025, reinforces the benefit of enzalutamide over non-steroidal anti-androgens in this setting. However, Sweeney’s presentation highlights that simply layering on more therapies isn’t a sustainable solution. The focus is now shifting towards identifying those patients most likely to respond to specific treatments, and avoiding unnecessary toxicity in those who won’t.
Current guidelines, as reflected in the Advanced Prostate Cancer Consensus Conference (APCCC) recommendations, stratify treatment based on tumor volume and metastatic presentation. While ADT with androgen receptor pathway inhibitors (ARPIs) remains the foundation, the addition of therapies like stereotactic body radiation therapy (SBRT) and docetaxel is increasingly common, particularly in patients with high-volume disease. Importantly, Sweeney emphasized the need to consider holistic patient factors – exercise, bone health, cardiovascular health, and psychosocial well-being – alongside purely oncological considerations.
The Promise and Pitfalls of Emerging Therapies
The presentation detailed a range of investigational therapies being explored to further improve outcomes in HSPC. PARP inhibition (niraparib), LuPSMA, and AKT inhibition (capivasertib) all showed signals of benefit in specific patient populations. However, Sweeney cautioned that the benefits observed to date are often modest and accompanied by significant adverse effects. The CAPItello-281 study with capivasertib, for example, showed a radiographic PFS benefit in PTEN-deficient tumors, but the overall survival benefit was less pronounced. Similarly, while LuPSMA demonstrated a PFS advantage, questions remain regarding long-term toxicities and the optimal patient selection criteria, particularly regarding SUVmean thresholds.
A recurring theme throughout Sweeney’s presentation was the challenge of identifying reliable biomarkers to predict treatment response. While PTEN status showed some promise as a predictor of AKT inhibitor benefit, its reliability was questioned. The search for a biomarker analogous to the PSA nadir for LuPSMA remains a key priority.
The Forward Look: Towards a Truly Personalized Approach
The immediate implication of Sweeney’s analysis is a call for increased participation in biomarker-driven clinical trials. Rather than relying solely on current standards of care, patients with metastatic HSPC should be actively considered for enrollment in studies evaluating novel therapies and biomarker strategies. This is not simply about access to cutting-edge treatments, but about contributing to the knowledge base that will ultimately define the future of care.
Looking ahead, several key developments are likely. We can expect to see:
- Increased Focus on Liquid Biopsies: The development of more sensitive and accurate liquid biopsy assays will be crucial for identifying biomarkers and monitoring treatment response in real-time.
- Refinement of Radiomic Biomarkers: Further research into imaging biomarkers, such as SUVmean for LuPSMA, will help refine patient selection criteria and optimize treatment strategies.
- Integration of Artificial Intelligence: AI-powered algorithms may be used to integrate clinical, genomic, and imaging data to predict treatment response and personalize therapy.
- A Shift in Regulatory Approvals: Regulatory bodies may increasingly require biomarker-driven strategies as part of drug approval processes, ensuring that therapies are targeted to the patients most likely to benefit.
Dr. Sweeney concluded by reiterating his continued support for current standards of care, but emphasized that the ultimate goal is to move beyond a “one-size-fits-all” approach and towards a truly personalized treatment paradigm for metastatic HSPC. This requires a commitment to rigorous research, biomarker discovery, and a willingness to challenge conventional wisdom.
Discover more from Archyworldys
Subscribe to get the latest posts sent to your email.
